Journal for Research in Applied Sciences and Biotechnology

ISSN: 2583-4053

Volume-2 Issue-2 || April 2023 || PP. 14-26

www.jrasb.com

https://doi.org/10.55544/jrasb.2.2.3

Plants Alkaloids Based Compound as Therapeutic Potential for Neurodegenerative

Rajnish Kumar Patel[1], Dushyant Gangwar[2], Harsh Gupta[3], Niloy Sharma[4] and Roshan Kumar[5]

[1]Department of Pharmacy, Guru Nanak College of Pharmaceutical Sciences, Dehradun-248007, Uttarakhand, INDIA.

[2]Department of Pharmacy, Guru Nanak College of Pharmaceutical Sciences, Dehradun-248007, Uttarakhand, INDIA.

[3]Department of Pharmacy, Guru Nanak College of Pharmaceutical Sciences, Dehradun-248007, Uttarakhand, INDIA.

[4]Department of Pharmacy, Guru Nanak College of Pharmaceutical Sciences, Dehradun-248007, Uttarakhand, INDIA.

[5]Assistant Professor, Department of Pharmacology, Guru Nanak College of Pharmaceutical Sciences, Dehradun-248007, Uttarakhand, INDIA.

[3]Corresponding Author: harsh089gupta@gmail.com

www.jrasb.com || Vol. 2 No. 2 (2023): April Issue

Received: 03-03-2023	**Revised:** 24-03-2023	**Accepted:** 03-04-2023

Graphical Abstract:



ABSTRACT

Although while getting a restful night's sleep is essential for your mental and physical health, insomnia is very prevalent. More people are turning to complementary and alternative therapies to treat or prevent sleeplessness. For hundreds of years, herbal treatments like valerian, passionflower, lemon balm, lavender, and California poppy have been utilized successfully. After using these herbal medicines, sleep latency was reduced and subjective and objective measures of sleep quality improved. Their sedative and sleep-inducing effects are caused by interactions with several neurotransmitter systems in the brain, according to molecular research. The plant species can be divided into 76 different genera and 32 different families, with the Asteraceae (24.2%) and Lamiaceae (21.1%) being the most prevalent subgroups. Leaves (29%) and flowers (27%), respectively, are used to make the majority of infusions (70%) and decoctions (25%). Just the most well-known taxa—out of the 106 known—are treated here (A. arvensis L., C. nepeta L., C. monogyna Jacq., H. lupulus L., L. nobilis L., L. angustifolia Mill., M. sylvestris L., M. chamomilla L., M. officinalis L., O. basilicum L., P. rhoeas L., P. somniferum L., R. officinalis L., T.

ISSN: 2583-4053
Volume-2 Issue-2 || April 2023 || PP. 14-26
https://doi.org/10.55544/jrasb.2.2.3

platyphyllus Scop., and V. officinalis L.). Further study is required to confirm the therapeutic potential of these substitutes and define the mechanism of action of bioactive compounds because only seven of the fifteen species chosen have been investigated for pharmacological activity as hypnotic-sedatives.

Keywords- Herbs, Insomnia, Alkaloids Compound, Neurodegenrative.

I. INTRODUCTION

Chronic insomnia affects 10% of adult Indians [1], and this percentage is growing [2]. Despite having enough time and conducive sleeping conditions, people with chronic insomnia frequently experience difficulties falling asleep or staying asleep [3,4]. Negative daytime effects include fatigue, difficulties concentrating, reduced social and occupational functioning, cognitive impairment, and emotional problems [3,4,5]. Moreover, there is a positive symbiotic association between sleep and general health [6,7,8]. Nowadays, getting a decent night's sleep is regarded as essential for cardiovascular health [9]. Patients with persistent insomnia are more likely to have cardiovascular disease, diabetes, arterial hypertension, depression, anxiety, and decreased cognitive function [8,10,11,12]. As a result, chronic insomnia has a high financial impact on both individuals and healthcare systems [2,13]. Both pharmaceutical and nonpharmacological treatments are available, and each has benefits and drawbacks of its own [14]. Despite this, there are still a lot of unmet demands in the standard therapeutic therapy for persistent insomnia, which is challenging for both patients and medical professionals. Clinical treatment in India varies greatly as a result of regional and national disparities in healthcare delivery. In order to identify these differences, the article's objective is to assess and compare the unmet needs in sickness management, medical practices, and healthcare policy throughout western Indian countries. We also discuss what lies ahead and what needs to be done right away to properly treat chronic insomnia in India. Insomnia is characterized by difficulty falling or staying asleep together with diminished daytime performance that cannot be linked to environmental sleep-disrupting factors such a lack of sleep-inducing circumstances, such as insomnia [15]. Chronic insomnia is defined as insomnia that occurs at least three times per week for three months [16]. Insomnia affects more than 30% of people worldwide at some stage [17]. Insomnia has a negative impact on a sufferer's mental and physical health [18]. Chronic insomnia is linked to shorter sleep duration, which increases the risk of CHD, MI, T2DM, obesity, hypertension, and all-cause mortality [19]. Those who have sleeplessness have a higher risk of having a psychiatric disorder [20]. Chronic sleep disturbance increases the likelihood of a depressive relapse, and insomnia is a significant risk factor for suicide [21]. Finally, the condition of chronic insomnia contributes to growing healthcare costs and a decline in quality of life [22]. Several studies have been conducted to prove the efficacy of cognitive behavioral treatment for insomnia (CBT-I) [23]. CBT-I, a multimodal strategy to treating insomnia that typically lasts for 5 weeks [24], includes relaxation training, cognitive restructuring, stimulus control, sleep restriction, and sleep hygiene education. It has been proven to be less harmful than pharmacological treatments for insomnia and just as effective, if not more so [25]. There is some evidence that CBT-I can have effects that endure longer than medication [26]. Importantly, rather than a decline in effectiveness, drug removal in these investigations was associated with a return of insomnia symptoms. Despite the advantages of CBT, many clinicians continue to recommend hypnotics as the first line of treatment for insomnia [27]. Two patient-based challenges to CBT-wider I's deployment include a shortage of qualified practitioners and time and financial limitations [28]. Access to CBT-I can be particularly difficult for persons who live in more rural locations. Patients with insomnia may find it difficult to participate in therapy because it can be expensive and time-consuming. Although more recent studies have shown that CBT-I enhances sleep as shown by greater subjective sleep ratings, there is less compelling objective evidence of CBT-beneficial I's effects on sleep [29]. As a result, hypnotic medicines are still frequently suggested by physicians since they are frequently seen to be required.

Since the dawn of time, medications have been used to treat insomnia [30]. By the turn of the 20th century, the use of barbiturates and comparable drugs to treat insomnia soared [31]. Around the middle of the 20th century, the use of barbiturates started to decline as more people learned about their harmful effects and the possibility of deadly overdose [32]. Chlordiazepoxide was the first benzodiazepine made available in the United States (US) and was initially made available in 1963 [33]. Flurazepam was the first benzodiazepine to receive FDA approval in 1970 [34] despite the fact that many other benzodiazepines have been developed for use as hypnotics. Due to their better safety reputation, benzodiazepines quickly replaced barbiturates in the treatment of insomnia [35]. The first non-benzodiazepine benzodiazepine receptor agonist (nBBRA) hypnotic, zolpidem, was released in the US in 1992 [36]. Essential oils (EO) are secondary metabolites produced by aromatic plants in a range of plant components, including buds, flowers, seeds, leaves, roots, fruits, wood, twigs, and bark [35,36,37]. EO is a blend of natural, volatile, aromatic compounds having a distinct odor. The conventional and unconventional extraction

ISSN: 2583-4053

Volume-2 Issue-2 || April 2023 || PP. 14-26

https://doi.org/10.55544/jrasb.2.2.3

strategies can be divided into two major categories. Common conventional techniques include hydrodistillation, Soxhlet extraction, water distillation, steam distillation, and organic-solvent extraction. Non-traditional extraction techniques include, for instance, accelerated solvent extraction (ASE), microwave assisted extraction (MAE), pressurized liquid extraction (PLE), negative pressure cavitation assisted extraction (NPCE), subcritical water extraction (SWE), supercritical fluid extraction (SFE), enzyme assisted extraction (EAE), high pressure (HP), and negative pressure cavitation assisted extraction (NPCE) (ASE). Since they increase productivity while reducing their negative effects on the environment, these non-thermal extraction techniques are regarded as "green" [36, 38].

II. ETIOLOGY

People who already experience sleep issues or who report being light sleepers on a regular basis are more likely to develop chronic insomnia. Mental health conditions like depression, anxiety, and post-traumatic stress disorder are all closely related to insomnia. [8-12] RLS, persistent pain, GERD, respiratory issues, and inactivity are all medical disorders that raise the risk of developing chronic insomnia. Problems with development can be linked to a child's susceptibility to developing sleep disorders. People who are perfectionists, ambitious, neurotic, low in extraversion, and prone to depression and anxiety are more likely to experience long-term insomnia. Disordered family relationships, divorce, losing a spouse, and abusing alcohol or other drugs are all instances of psychosocial stressors that are linked to a higher risk of sleeplessness.

III. ROLE OF ESSENTIAL OIL IN INSOMNIA DISEASE

It is widely believed that alterations in brain neurotransmitter and metabolite levels play a key role in the development of psychiatric disorders. The inhibitory neurotransmitter GABA mediates synaptic transmission in the brain and the rest of the nervous system. Inhibiting action potentials and exerting postsynaptic inhibition [39] by binding to its receptors and increasing potassium and chloride ion permeability of cell membranes, especially the massive inward flow of chloride ions. One of the major causes of physiological insomnia is insufficient GABA in the brain, which can keep neurons in an impulsive excitation state for an extended period of time. Since GABA cannot cross the blood-brain barrier (BBB) and Glu serves as a precursor to GABA in the brain, researchers frequently use the Glu:GABA ratio as a quantitative measure of the excitation/inhibition balance in the CNS. The monoamine neurotransmitters 5-hydroxytryptamine (5-HT), dopamine (2-DA), and norepinephrine (NE) are all involved in regulating sleep and wakefulness, respectively [40,41].

PACA-induced insomnia rats benefit from AEO treatment. Rats in the model group had significantly lower levels of 5-OH in their brains compared to the control group, and AEO administration resulted in significantly higher levels of 5-HT, lower levels of DA and NE, higher GABA levels, and lower Glu levels, leading to a significantly lower Glu/GABA ratio [42]. One mechanism of incense's sedative-hypnotic effects in clinical settings may be the inward flow of chloride ions, as discovered by Wang, who also found that AEO boosted synthesis and release of GABA and increased expression of GABAA receptors [43,44]. At the same time, flumazenil, a competitive antagonist of the benzodiazepine site of the GABA receptor, effectively counteracted the sleep-inducing effects of AEO. This latter effect was found to be dose-dependent, indicating that the GBBAergic system was the primary target of the essential oil's sedative and sleep-inducing properties [45].

Kao found that after 7 days of administering Kynam (also known as Chi-Nan) to mice, serum serotonin (5-OH) levels increased from 551 344 ng/mL to 952 334 ng/mL, suggesting that Kynam may exhibit sedative and antidepressant effects [46,47]. Dopaminergic synapses, 5-hydroxytryptaminergic synapses, GABAergic synapses, long-term depression, and neuroactive ligand-receptor interactions were all found to be impacted by Kynam in a microarray study of RNA profiles in mouse brains [48,49]. These findings in mice indicate that increased 5-OH levels and multiple neuroactive pathways may be associated with the anxiolytic and antidepressant effects of agarwood.



Fig: 1 Model of the pathophysiology of insomnia. GABA 5 g -aminobutyric acid; SNP 5 single-nucleotide polymorphism

IV. LIST OF HERBS ALKALOIDS FOR INSOMNIA DISEASE

Mitragyna speciosa Korth was the first plant from which the indole alkaloid mitragynine was isolated. In a mouse model of depression, the forced swim test (FST) and the tail suspension test (TST) were employed to measure the antidepressant efficacy of mitragynine.

Journal for Research in Applied Sciences and Biotechnology

ISSN: 2583-4053

Volume-2 Issue-2 || April 2023 || PP. 14-26

www.jrasb.com

https://doi.org/10.55544/jrasb.2.2.3

Without influencing locomotor activity in the open-field test, mitragynine dramatically decreased immobility durations in mice during the FST and TST at doses of 10 and 30 mg/kg. When rats exposed to the FST and TST were given mitragynine at levels that had positive antidepressant effects, corticosterone secretion was significantly reduced [50,51]. Lyaloside and strictosamide both had a negligible monoamine oxidase (MAO) inhibiting action. Nonetheless, these substances might inspire new approaches to creating analogs that could treat depression. Lyaloside and stratosamide's half-maximal inhibitory concentrations (IC50) against MAO-A were 50.04 1.09 and 132.5 1.33 g/mL, respectively, while their IC50 against MAO-B were 306.6 1.40 and 162.8 1.26 g/mL. Lyaloside was produced by Psychotria suterella, whereas strictosamide was produced by Psychotria laciniata [52]. Harmane, norharmane, and harmine all demonstrated antidepressant-like effects in mice that underwent the forced swimming test (FST). These drugs had an ED50 of 11.5 mg/kg for harmane, 8.5 mg/kg for norharmane, and 8 mg/kg for harmine, which resulted in a shorter duration of immobility. Instead of presynaptic monoaminergic processes, it seems that an inverse-agonistic pathway involving the benzodiazepine receptors is in charge of these effects [53,54]. The drug psychollatine was derived from the botanical Psychotria umbellata. Psychollatine increased the quantity of crossings, rearings, and head-dips in the treated mice during the hole-board test at doses of 7.5 and 15 mg/kg. In the light/dark test, psychollatine at a dose of 7.5 mg/kg resulted in subjects spending more time in the light area and delaying their first entry into the dark compartment. Psychollatine significantly decreased the amount of time mice stayed motionless in the FST at doses of 3 and 7.5 mg/kg.[55]



Fig: 2 Alkaloid Compound Beneficial for Insomnia Disease

***4.1. Anthemis arvensis* L.**

Anthemis arvensis L., sometimes known as corn chamomile, is an annual herbaceous plant with Indian origins. This particular chamomile differs from the more popular variety in that its inside receptacle is full. Its digestive, antispasmodic, anti-inflammatory, and emetic effects are also used by practitioners of folk medicine [56,57].

Sesquiterpene lactones called germacranolides, eudesmanolides, and guaianolides characterize the genus Anthemis in its phytochemical profile [57]. In particular, two known sesquiterpene lactones, antheindurolides A and B, together with five new related lactones (5-Hydroxy-5,6-dihydro-6,13-dehydro-antheindurolide A; 5-Acetoxy-5,6-dihydro-6,13-dehydro-antheindurolide A; 6-Hydroxy-5,6-dihydro-4,5-dehydro-antheindurolide A; Antheindurolide A-5,6-oxide; and 6-hydroperoxy-5,6-dihydro-4,5-dehydro-antheindurolide A) with the same unusual skeleton, have been isolated from the aerial parts of Anthemis arvensis [58].

Although it is one of the species most commonly mentioned in Italian folk medicine for its calming qualities, to the best of our knowledge, there are no scholarly articles about pre-clinical and clinical investigations of corn chamomile for the treatment of insomnia and anxiety. [59][60] In-vitro and in-vivo studies are needed to further understand its typical use as a sedative and its mode of action.

***4.2. Clinopodium nepeta* L.**

Nepeta is the scientific name for the tall herbaceous perennial, Clinopodium nepeta (L.) Kuntze subsp. nepeta, which is native to southern India. Less calamint is frequently used as a garnish on salads and soups [59,60,61]. Because of its relaxing effects, lesser calamint can be used as an emollient, a natural cure for toothaches, diarrhea, and other conditions [59,63,62].

Lesser calamint essential oils can be found all over the world and in various parts of Italy; Bozovic and Ragno provide extensive descriptions of the compositions of these essential oils (2017). There are three different types of oil that can be processed from lesser calamint. The earliest and most popular one has numerous other compounds in addition to pulegone as its main component. They include piperitenone, piperitone, menthol and its isomers, menthone, isomenthone, and menthol and its isomers. The second type is characterized by the existence of piperitenone oxide and/or piperitone oxide, whereas the third chemotype is characterized by the dominance of carvone and 1,8-cineole [63].

Lesser calamint has long been used in traditional medicine to treat insomnia, depression, convulsions, and cramps in addition to its antifungal and antioxidant qualities [64, 65, 66]. Pulegone, menthone, 1,8-cineole, and carvone are among the compounds in essential oil that appear to be principally in charge of these actions [67,68.69]. It has been demonstrated that carvone prolongs the time that mice spend sleeping after

ISSN: 2583-4053
Volume-2 Issue-2 || April 2023 || PP. 14-26

https://doi.org/10.55544/jrasb.2.2.3

receiving pentobarbital [70] and lessens the mice's locomotor activity. However, there is no evidence to support the sedative and anxiolytic properties of lower calamint.

4.3. Crataegus monogyna Jacq.

Hawthorn, formally known as Crataegus monogyna Jacq., is a tiny tree or blossoming shrub that originated in northwest Africa, west Asia, and India. Flowers are composed of five white petals, numerous red stamens, and dense corymbs. They have a light scent. The leaves are divided into lobes. The fruit, which is actually a pome and has a single seed within, has the appearance of a red berry. In traditional Chinese medicine, hawthorn is frequently used as a sedative and hypotensive [71,72].

Scientific research has demonstrated that Crataegus species are a dietary, nutraceutical, and bioactive chemical source [73,74]. According to a thorough chemical and bioactive characterization of C. monogyna, the fruits that are overripe have the highest concentrations of carbohydrates (glucose, fructose, sucrose, and trehalose), the flowers have the highest concentrations of tocopherols (159.84 mg/100g of dry weight) and ascorbic acid (408.37 mg/100 g of dry weight), and the best n-6/n-3 fatty acid ratio.

Hawthorn extract has long been used by herbalists for its curative effects [75,76]. Today, hawthorn extracts and other preparations are frequently used to treat problems like angina, high blood pressure, irregular heartbeats, heart failure, and excessive cholesterol [77,78,79]. There hasn't been much study done on how C. monogyna affects the central nervous system. Hawthorn pulp and seed extracts demonstrated analgesic efficacy in rats and inhibited exploratory behaviors in hole-board trials and spontaneous locomotion in activity cage tests [80,81], suggesting that this plant may be effective for treating stress, anxiety, sleep difficulties, and pain control. In a more recent study [82], hawthorn and chlordiazepoxide equally reduced the anxiety of sixty female laboratory mice. The experimental groups included control (no anxiety and no injection; n = 10), anxiety (no injection; n = 10), chlordiazepoxide (1.2 mg/kg intraperitoneal dose; n = 10), and treatment (50, 100, and 200 mg/kg intraperitoneal dose; n = 30). Once volunteers were exposed to dark boxes, anxiety levels were tested using a plus rated maze. The results show that hawthorn extract reduces anxiety levels; specific dosages of 100 and 200 mg/kg are suggested as effective substitutes for chlordiazepoxide in the management of anxiety responses [83,84]. In a new randomized, placebo-controlled research, hawthorn fruit extract was given to 60 participants with hypertension and sleep issues to determine if it would help lower their blood pressure. The severity of sleep disorders was significantly less severe in the group treated with C. monogyna extract, according to results from the Pittsburgh questionnaire (p = 0.001) [85], and post-treatment data showed that the intervention group's systolic and diastolic blood pressure was significantly better than the placebo group's.

***4.4. Humulus lupulus* L.**

Common hop (Humulus lupulus L.), a dioecious, rhizomatous, perennial, herbaceous, and climbing plant, is a native of India, southwestern Asia, and North America. The female flowers are grouped in cones, and the third through fifth leaves have sharp lobed edges. Young shoots are frequently used in salads, soups, and omelets [86,87]. Among the conditions this plant can treat are dysmenorrhea [88], digestive infusion from the blossoms [89], and toothache [90].

Many published studies on the phytochemistry of H. lupulus exist. Monoterpenes (up to 57.9% b-myrcene) and sesquiterpenes (up to 51.2% -humulene, 14.7% -caryophyllene, 14% -elemene, and 10.2% -selinene) are the main ingredients of hops essential oil [174]. According to Akazawa et al., several triterpenoids, including -amyrin, -amyrin, -amyrin, lupeol, ursa-9(11), and 12-dien-3b-ol [90] have been discovered in hop cones (91,92,93). Hops include compounds from five different groups of flavonoids and derivatives, the majority of which are concentrated in the seeds and bracts of female inflorescences: chalcones, flavanones, flavonols, flavan-3-ols, and kaempferol. The bulk of the hydroxycinnamic acids in hops are composed of caffeine, ferulic acid, and sinapic acid, while the majority of the hydroxybenzoic acids are composed of gallic acid, syringic acid, and vanillic acid [94,95]. The bitter acid equivalents humulone and lupulone are the most prevalent phloroglucinol derivatives found in hops [96,97]. Bitter acids come in two different varieties: humulone-derived -acids and -acids (derived from lupulone).

Researchers Zanoli, Rivasi, Zavatti, Brusiani, and Baraldi examined the effects of hops CO2 extract and its fraction containing a-bitter acids on the central nervous systems of rats [98,99]. Starting at an effective level of 10 mg/kg, both extracts improved pentobarbital's ability to induce sleep. The extracts had no impact on the elevated plus-maze test or the open-field test for rat locomotion. These results suggest that the increased pentobarbital effect is mostly due to the beta-acid-containing H. lupulus fraction.

Similar results were reported in later investigations using higher dosages (100 and 200 mg/kg) of H. lupulus ethanolic and CO_2 extracts to examine their sedative effects after oral administration in mice [100]. They discovered, in particular, that the sedative effect was caused by three categories of components in lipophilic hops extracts; the most potent of these were -bitter acids, followed by -bitter acids and hop oil extract. Hops' sedative effects have been attributed to xanthohumol and 2-methyl-3-buten-2-ol [101,102].

Another study utilizing female young adult quails discovered that the motor activity of the animals considerably decreased after being given hops dry extract for 14 days at doses of 3.80, 7.60, and 41.80 mg/kg body weight [103,104].

ISSN: 2583-4053
Volume-2 Issue-2 || April 2023 || PP. 14-26
https://doi.org/10.55544/jrasb.2.2.3

Hops dried extracts may have neuropharmacological effects because several of the plant's compounds interact with melatonin and serotonin receptors (ML1 and 5-HT6; IC50 values of 71 g/mL and 21 g/mL, respectively) [105,110].

In clinical investigations looking at their sedative and anxiolytic effects, hops have been combined with other plants such valerian and rosemary [111,112]. It is still unclear how hops actually works to cure mental and sleep issues based on clinical studies. Hop strobile medicines have been demonstrated to enhance sleep and lower mental tension, however the Committee on Herbal Medicinal Products (HMPC) made this conclusion based on their "traditional use" [113]. The efficacy of these herbal remedies seems plausible, and there is proof that they have been used in this manner for at least 30 years (including at least 15 years within the EU) [114] while remaining safe. There aren't enough clinical study data available, though.

***4.5. Matricaria chamomilla* L.**

Although it has naturalized in many other areas, the annual herbaceous plant chamomile (Matricaria chamomilla L.) is native to South-West Asia and South-Eastern India. A center disc of yellow tubulose flowers with a ring of white ligulate ray flowers make up a capitulum. They have a conical receptacle and are hollow on the inside. The lanceolate forms of tripinnate or bipinnate leaves have been condensed to laciniae. Inflorescences are the main plant parts used to prepare infusions in traditional phytotherapy.[115][116]

In chamomile flowers, more than 120 metabolites from a variety of chemical groups have been identified [118], including amino acids, carbohydrates, flavonoids, coumarins, vitamins, and fatty acids. Sesquiterpenes and their derivatives, such as a-farnesene (29.8%), b-farnesene (9.3%), -bisabolol and its oxide (15.7%), chamazulene (6.4%), germacrene D (6.2%), and spiroether (5.6%) are abundant in M. chamomilla essential oil [207]. Herniarin and umbelliferone are coumarins; apigenin, luteolin, and their glucosides are flavones; quercetin, rutin, and naringenin are flavonols; and naringenin is a flavanone. Chlorogenic acid and caffeic acid are phenylpropanoids.

Chamomile is frequently used as a carminative [119,120,121], a spasmolytic [122,123,124], and for the treatment of dysmenorrhea [125,126] in addition to its soothing effects. The hydro-alcoholic extracts of M. chamomilla inflorescences have relaxing and antispasmodic effects in addition to antioxidant, hypoglycemic, and anticancer activities [127,128,129]. Although little is known about how exactly they function, chamomile flower extracts are used as an alternate or additional treatment for anxiety and insomnia. Up until this time, some of the reports have been disputed. The flavonoid apigenin in chamomile is hypothesized to be responsible for its calming effects as a ligand for central BZD receptors [130]. This flavonoid competitively reduced flunitrazepam binding at a Ki of 4 M, indicating that it may be used as a sedative and anxiolytic but not as an anticonvulsant or myorelaxant [131]. It had no impact on the binding of muscimol to GABAA receptors, 1-adrenoceptors, or muscarinic receptors. According to study by Avallone, Zanoli, Puia, Kleinschnitz, Schreier, and Baraldi from 2000, the sedative effect of apigenin is not mediated by BZD receptors because of their extremely low affinity for each other. This contradicts earlier findings. Moreover, studies using electrophysiological methods on cerebellar granule cells in culture revealed that apigenin suppressed GABA-activated Cl currents, suggesting that other substances with BZD-like activity may be in charge of the calming effect of M. chamomilla extracts [132,133].

By Zanoli, Avallone, and Baraldi (2000) [134], the apigenin in chamomile was also investigated for its sedative and anxiolytic properties. Apigenin was administered to rats at a dose of 25 mg/kg, and although it had no anxiolytic effects in this study, it did reduce locomotor activity. Later, Awad, Levac, Cybulska, Merali, Trudeau and Arnason (2007) performed in vitro assay on rat brain homogenate to determine whether anxiolytic plants (such as M. chamomilla, Centella asiatica, Eschscholtizia californica, Humulus lupulus, Hypericum perforatum, Melissa officinalis, Passiflora incarnata, Piper methysticum, Scutellaria lateriflora, and Valeriana officinalis) interact with GluAD or GABA-T, consequently altering the level of GABA in the brain [135]. While GluAD activity was increased by over 40% when treated with 1 mg of extracts from C. asiatica and V. officinalis, GABA-T activity was most effectively inhibited by M. officinalis extract (IC50 = 0.35 mg/mL).

The fact that both chamomile and hops extracts considerably reduced GluAD activity (0.11-0.65 mg/mL) shows that GABA metabolism is not likely to be involved in M. chamomilla's anxiolytic effects. Few clinical studies examining the anxiolytic properties of chamomile have been published. The first randomized, double-blind research involved 61 participants with mild to moderate generalized anxiety disorder and lasted for 8 weeks [136][137].

The mean overall HAMA (Hamilton Anxiety Rating) score significantly differed between the chamomile and placebo treatments ($p = 0.047$), suggesting that M. chamomilla has some calming effects. 179 people with generalized anxiety disorder (GAD) took part in this trial between March 2010 and June 2015, and the same research team afterwards evaluated how well long-term chamomile consumption prevented symptom relapse. Findings revealed significantly less GAD symptoms in chamomile patients than in placebo patients ($p = 0.0032$) [130], and the mean duration to relapse was 11.4 8.4 weeks as opposed to 6.3 3.9 weeks.[138-140] There is a need for more in vitro, preclinical, and clinical research on chamomile flower extract as a treatment for anxiety and restlessness.

ISSN: 2583-4053

Volume-2 Issue-2 || April 2023 || PP. 14-26

https://doi.org/10.55544/jrasb.2.2.3

V. CONCLUSION

Chronic insomnia results in significant, and frequently unrecognized, expenditures for people and healthcare systems. Untreated chronic insomnia adds to India's overall disease burden and raises healthcare costs. In spite of this, India's healthcare systems continue to disregard chronic insomnia. So that Indian citizens receive the level of care to which they are legally entitled, this must be improved. The current management strategy is inadequate in part because existing medications are used less-than-optimally, and there are therapeutic gaps that need to be filled with novel procedures and pharmaceuticals (and more frequently than not off-label for pharmacological treatments). The study of sleep medicine must be legally codified and recognized as a separate medical specialization worldwide in order to address these needs. We have the following recommendations for developing this further:

In all the states of India, it is crucial to create scientific societies for sleep medicine. Each undergraduate medical curriculum should include a requirement for teaching general practitioners and other pertinent experts how to specifically manage sleeplessness. It is crucial to develop materials that patients can access quickly and with confidence. It is impossible to exaggerate the value of patient advocacy and education organizations. Based on universal consensus, healthcare professionals (HCPs) everywhere should receive training in diagnosing and treating insomnia. Online CBT-I needs to be more widely accessible. Pharmacotherapies may be used as a backup treatment option when cognitive behavioral therapy for depression (CBT-I) fails or is not accessible. It is necessary to provide further details regarding the use of CBT-I as an extra method of treatment. It is necessary to create a network of specialized sleep clinics across the country. It is important to include centers for cognitive behavior therapy for insomnia in preventative healthcare programs so that patients with chronic sleep issues can more easily obtain CBT-I and collaborate with primary care doctors. The long-term implications of chronic insomnia and the effectiveness of treatment must be characterized. New drugs with unique mechanisms of action also need to be investigated.

REFERENCES

[1] American Psychiatric Association, D., & American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders: DSM-5* (Vol. 5, No. 5). Washington, DC: American psychiatric association.

[2] Brooks, S. K., Webster, R. K., Smith, L. E., Woodland, L., Wessely, S., Greenberg, N., & Rubin, G. J. (2020). The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *The lancet*, *395*(10227), 912-920.

[3] Morais, L. H., Schreiber IV, H. L., & Mazmanian, S. K. (2021). The gut microbiota–brain axis in behaviour and brain disorders. *Nature Reviews Microbiology*, *19*(4), 241-255.

[4] Santomauro, D. F., Herrera, A. M. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M., ... & Ferrari, A. J. (2021). Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *The Lancet*, *398*(10312), 1700-1712.

[5] Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., ... & Liu, X. (2022). Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *The Lancet Public Health*, *7*(2), e105-e125.

[6] Yadav, A. N., Verma, P., Kumar, R., Kumar, V., & Kumar, K. (2017). Current applications and future prospects of eco-friendly microbes. *EU Voice*, *3*(1), 21-22.

[7] Lee, S. A. (2020). Coronavirus Anxiety Scale: A brief mental health screener for COVID-19 related anxiety. *Death studies*, *44*(7), 393-401.

[8] Jiao, W. Y., Wang, L. N., Liu, J., Fang, S. F., Jiao, F. Y., Pettoello-Mantovani, M., & Somekh, E. (2020). Behavioral and emotional disorders in children during the COVID-19 epidemic. *The journal of Pediatrics*, *221*, 264-266.

[9] Guessoum, S. B., Lachal, J., Radjack, R., Carretier, E., Minassian, S., Benoit, L., & Moro, M. R. (2020). Adolescent psychiatric disorders during the COVID-19 pandemic and lockdown. *Psychiatry research*, *291*, 113264.

[10] Kumar, R., Saha, P., Lokare, P., Datta, K., Selvakumar, P., & Chourasia, A. (2022). A Systemic Review of Ocimum sanctum (Tulsi): Morphological Characteristics, Phytoconstituents and Therapeutic Applications. *International Journal for Research in Applied Sciences and Biotechnology*, *9*(2), 221-226.

[11] Ohayon, M. M., & Reynolds III, C. F. (2009). Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD). *Sleep medicine*, *10*(9), 952-960.

[12] Kocevska, D., Lysen, T. S., Dotinga, A., Koopman-Verhoeff, M. E., Luijk, M. P., Antypa, N., ... & Tiemeier, H. (2021). Sleep characteristics across the lifespan in 1.1 million people from the Netherlands, United Kingdom and United States: a systematic review and meta-analysis. *Nature human behaviour*, *5*(1), 113-122.

[13] Umama, Y., Venkatajah, G., Shourabh, R., Kumar, R., Verma, A., Kumar, A., & Gayoor, M. K. (2019). Topic-The scenario of pharmaceuticals and development of microwave as; sisted extraction technique. *World J Pharm Pharm Sci*, *8*(7), 1260-1271.

[14] Trauer, J. M., Qian, M. Y., Doyle, J. S., Rajaratnam, S. M., & Cunnington, D. (2015). Cognitive

ISSN: 2583-4053
Volume-2 Issue-2 || April 2023 || PP. 14-26

https://doi.org/10.55544/jrasb.2.2.3

behavioral therapy for chronic insomnia: a systematic review and meta-analysis. *Annals of internal medicine*, *163*(3), 191-204.

[15] Morin, C. M., & Benca, R. (2012). Chronic insomnia. *The Lancet*, *379*(9821), 1129-1141.

[16] Morin, C. M., Drake, C. L., Harvey, A. G., Krystal, A. D., Manber, R., Riemann, D., & Spiegelhalder, K. (2015). Insomnia disorder. *Nature reviews Disease primers*, *1*(1), 1-18.

[17] Kessler, R. C., Berglund, P. A., Coulouvrat, C., Hajak, G., Roth, T., Shahly, V., ... & Walsh, J. K. (2011). Insomnia and the performance of US workers: results from the America insomnia survey. *Sleep*, *34*(9), 1161-1171.

[18] Awuchi, C. G., Amagwula, I. O., Priya, P., Kumar, R., Yezdani, U., & Khan, M. G. (2020). Aflatoxins in foods and feeds: A review on health implications, detection, and control. *Bull. Environ. Pharmacol. Life Sci*, *9*, 149-155.

[19] Van Laethem, M., Beckers, D. G., Kompier, M. A., Dijksterhuis, A., & Geurts, S. A. (2013). Psychosocial work characteristics and sleep quality: a systematic review of longitudinal and intervention research. *Scandinavian journal of work, environment & health*, 535-549.

[20] Santoso, A. M., Jansen, F., de Vries, R., Leemans, C. R., van Straten, A., & Verdonck-de Leeuw, I. M. (2019). Prevalence of sleep disturbances among head and neck cancer patients: a systematic review and meta-analysis. *Sleep medicine reviews*, *47*, 62-73.

[21] Bind, A., Das, S., Singh, V. D., Kumar, R., Chourasia, A., & Saha, P. (2020). Natural Bioactives For The Potential Management Of Gastric Ulceration. *Turkish Journal of Physiotherapy and Rehabilitation*, *32*(3), 221-226.

[22] Aernout, E., Benradia, I., Hazo, J. B., Sy, A., Askevis-Leherpeux, F., Sebbane, D., & Roelandt, J. L. (2021). International study of the prevalence and factors associated with insomnia in the general population. *Sleep Medicine*, *82*, 186-192.

[23] Ree, M., Junge, M., & Cunnington, D. (2017). Australasian Sleep Association position statement regarding the use of psychological/behavioral treatments in the management of insomnia in adults. *Sleep medicine*, *36*, S43-S47.

[24] Kumar, R., & Saha, P. (2022). A review on artificial intelligence and machine learning to improve cancer management and drug discovery. *International Journal for Research in Applied Sciences and Biotechnology*, *9*(3), 149-156.

[25] Dodds, K. L., Miller, C. B., Kyle, S. D., Marshall, N. S., & Gordon, C. J. (2017). Heart rate variability in insomnia patients: A critical review of the literature. *Sleep medicine reviews*, *33*, 88-100.

[26] Shallcross, A. J., Visvanathan, P. D., Sperber, S. H., & Duberstein, Z. T. (2019). Waking up to the problem of sleep: can mindfulness help? A review of theory and evidence for the effects of mindfulness for sleep. *Current Opinion in Psychology*, *28*, 37-41.

[27] Roshan, K. (2020). Priya damwani, Shivam kumar, Adarsh suman, Suthar Usha. An overview on health benefits and risk factor associated with coffee. *International Journal Research and Analytical Review*, *7*(2), 237-249.

[28] Pillai, V., Roth, T., Mullins, H. M., & Drake, C. L. (2014). Moderators and mediators of the relationship between stress and insomnia: stressor chronicity, cognitive intrusion, and coping. *Sleep*, *37*(7), 1199-1208A.

[29] Chen, M. C., Chang, C., Glover, G. H., & Gotlib, I. H. (2014). Increased insula coactivation with salience networks in insomnia. *Biological Psychology*, *97*, 1-8.

[30] Jackson, M. L., Sztendur, E. M., Diamond, N. T., Byles, J. E., & Bruck, D. (2014). Sleep difficulties and the development of depression and anxiety: a longitudinal study of young Australian women. *Archives of women's mental health*, *17*, 189-198.

[31] Lopresti, A. L., Smith, S. J., & Drummond, P. D. (2021). An investigation into an evening intake of a saffron extract (affron®) on sleep quality, cortisol, and melatonin concentrations in adults with poor sleep: a randomised, double-blind, placebo-controlled, multi-dose study. *Sleep Medicine*, *86*, 7-18.

[32] Roth, T., Jaeger, S., Jin, R., Kalsekar, A., Stang, P. E., & Kessler, R. C. (2006). Sleep problems, comorbid mental disorders, and role functioning in the national comorbidity survey replication. *Biological psychiatry*, *60*(12), 1364-1371.

[33] Kumar, R., Saha, P., Nyarko, R. O., Kahwn, I., Boateng, E. A., Boateng, P. O., ... & Bertram, A. (2021). Role of Cytokines and Vaccines in Break through COVID 19 Infections. *Journal of Pharmaceutical Research International*, *33*(60B), 2544-2549.

[34] Kumar, R., Sood, U., Gupta, V., Singh, M., Scaria, J., & Lal, R. (2020). Recent advancements in the development of modern probiotics for restoring human gut microbiome dysbiosis. *Indian journal of microbiology*, *60*, 12-25.

[35] Drake, C. L., Pillai, V., & Roth, T. (2014). Stress and sleep reactivity: a prospective investigation of the stress-diathesis model of insomnia. *Sleep*, *37*(8), 1295-1304

[36] Daharia, A., Jaiswal, V. K., Royal, K. P., Sharma, H., Joginath, A. K., Kumar, R., & Saha, P. (2022). A Comparative review on ginger and garlic with their pharmacological Action. *Asian Journal of Pharmaceutical Research and Development*, *10*(3), 65-69.

[37] Hertenstein, E., Feige, B., Gmeiner, T., Kienzler, C., Spiegelhalder, K., Johann, A., ... & Baglioni, C. (2019). Insomnia as a predictor of mental disorders: a systematic review and meta-analysis. *Sleep medicine reviews*, *43*, 96-105.

ISSN: 2583-4053

Volume-2 Issue-2 || April 2023 || PP. 14-26

https://doi.org/10.55544/jrasb.2.2.3

[38] Riemann, D., Krone, L. B., Wulff, K., & Nissen, C. (2020). Sleep, insomnia, and depression. *Neuropsychopharmacology*, *45*(1), 74-89.

[39] Van Laethem, M., Beckers, D. G., Kompier, M. A., Dijksterhuis, A., & Geurts, S. A. (2013). Psychosocial work characteristics and sleep quality: a systematic review of longitudinal and intervention research. *Scandinavian journal of work, environment & health*, 535-549

[40] Sahana, S. (2020). Purabi saha, Roshan kumar, Pradipta das, Indranil Chatterjee, Prasit Roy, Sk Abdur Rahamat. *A Review of the 2019 Corona virus (COVID-19) World Journal of Pharmacy and Pharmaceutical science*, *9*(9), 2367-2381.

[41] Shinjyo, N., Waddell, G., & Green, J. (2020). Valerian root in treating sleep problems and associated disorders—A systematic review and meta-analysis. *Journal of Evidence-Based Integrative Medicine*, *25*, 2515690X20967323.

[42] Raj, A., Tyagi, S., Kumar, R., Dubey, A., & Hourasia, A. C. (2021). Effect of isoproterenol and thyroxine in herbal drug used as cardiac hypertrophy. *Journal of Cardiovascular Disease Research*, 204-217.

[43] Kalmbach, D. A., Cuamatzi-Castelan, A. S., Tonnu, C. V., Tran, K. M., Anderson, J. R., Roth, T., & Drake, C. L. (2018). Hyperarousal and sleep reactivity in insomnia: current insights. *Nature and science of sleep*, 193-201.

[44] Sahana, S. (2020). Roshan kumar, Sourav nag, Reshmi paul, Nilayan guha, Indranil Chatterjee. A Review on Alzheimer disease and future prospects. *World Journal of Pharmacy and Pharmaceutical science*, *9*(9), 1276-1285.

[45] Kumar, R., & Dubey, A. (2020). Phytochemical Investication And Heptoprotective Evalution Acacia Rubica Extract Isonized And Paracetamol Indused Animal Toxicity. *Turkish Journal of Physiotherapy and Rehabilitation*, *32*(3), 65-69.

[46] Krystal, A. D., Prather, A. A., & Ashbrook, L. H. (2019). The assessment and management of insomnia: an update. *World Psychiatry*, *18*(3), 337-352.

[47] Wickwire, E. M., Shaya, F. T., & Scharf, S. M. (2016). Health economics of insomnia treatments: the return on investment for a good night's sleep. *Sleep medicine reviews*, *30*, 72-82.

[48] Drummond, S. P., Walker, M., Almklov, E., Campos, M., Anderson, D. E., & Straus, L. D. (2013). Neural correlates of working memory performance in primary insomnia. *Sleep*, *36*(9), 1307-1316.

[49] Zhou, Q., Yu, C., Yu, H., Zhang, Y., Liu, Z., Hu, Z., ... & Zhou, D. (2020). The effects of repeated transcranial direct current stimulation on sleep quality and depression symptoms in patients with major depression and insomnia. *Sleep Medicine*, *70*, 17-26.

[50] Chen, Min, Jun Yang, Xuan Zhu, Xiaofei Wang, Mengchen Liu, and Jeungeun Song. "Smart home 2.0: Innovative smart home system powered by botanical IoT and emotion detection." *Mobile Networks and Applications* 22 (2017): 1159-1169.

[51] Kumar, R., Saha, P., Sarkar, S., Rawat, N., & Prakash, A. (2021). A Review On Novel Drug Delivery System. *IJRAR-International Journal of Research and Analytical Reviews (IJRAR)*, *8*(1), 183-199.

[52] Kumar, R., Saha, P., Kumar, Y., Sahana, S., Dubey, A., & Prakash, O. (2020). A Review on Diabetes Mellitus: Type1 & Type2. *World Journal of Pharmacy and Pharmaceutical Sciences*, *9*(10), 838-850.

[53] Alegria, M., Shrout, P. E., Canino, G., Alvarez, K., Wang, Y., Bird, H., ... & Duarte, C. (2019). The effect of minority status and social context on the development of depression and anxiety: a longitudinal study of Puerto Rican descent youth. *World Psychiatry*, *18*(3), 298-307

[54] Mellinger, G. D., Balter, M. B., & Uhlenhuth, E. H. (1985). Insomnia and its treatment: prevalence and correlates. *Archives of general psychiatry*, *42*(3), 225-232.

[55] Kredlow, M. A., Capozzoli, M. C., Hearon, B. A., Calkins, A. W., & Otto, M. W. (2015). The effects of physical activity on sleep: a meta-analytic review. *Journal of behavioral medicine*, *38*, 427-449.

[56] Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., ... & Zamorano, J. L. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). *European heart journal*, *43*(41), 4229-4361.

[57] Halvorsen, S., Mehilli, J., Cassese, S., Hall, T. S., Abdelhamid, M., Barbato, E., ... & Zacharowski, K. (2022). 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC). *European heart journal*, *43*(39), 3826-3924.

[58] Saha, P., Nyarko, R. O., Lokare, P., Kahwa, I., Boateng, P. O., & Asum, C. (2022). Effect of Covid-19 in Management of Lung Cancer Disease: A Review. *Asian Journal of Pharmaceutical Research and Development*, *10*(3), 58-64.

[59] Paolisso, P., Bergamaschi, L., Santulli, G., Gallinoro, E., Cesaro, A., Gragnano, F., ... & Pizzi, C. (2022). Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. *Cardiovascular Diabetology*, *21*(1), 1-12.

[60] Tan, Y. Q., Lin, F., Ding, Y. K., Dai, S., Liang, Y. X., Zhang, Y. S., ... & Chen, H. W. (2022). Pharmacological properties of total flavonoids in

ISSN: 2583-4053
Volume-2 Issue-2 || April 2023 || PP. 14-26
https://doi.org/10.55544/jrasb.2.2.3

Scutellaria baicalensis for the treatment of cardiovascular diseases. *Phytomedicine*, 154458.
[61] Sahana, S., Kumar, R., Nag, S., Paul, R., Chatterjee, I., & Guha, N. (2020). A Review On Alzheimer Disease And Future Prospects.
[62] Ford, D. E., & Kamerow, D. B. (1989). Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention?. *Jama*, *262*(11), 1479-1484.
[63] Kumar, R., Saha, P., Pathak, P., Mukherjee, R., Kumar, A., & Arya, R. K. (2009). Evolution Of Tolbutamide In The Treatment Of Diabetes Mellitus. *Jour. of Med. P'ceutical & Alli. Sci*, *9*.
[64] Freeman, D., Sheaves, B., Waite, F., Harvey, A. G., & Harrison, P. J. (2020). Sleep disturbance and psychiatric disorders. *The Lancet Psychiatry*, *7*(7), 628-637.
[65] Hertenstein, E., Feige, B., Gmeiner, T., Kienzler, C., Spiegelhalder, K., Johann, A., ... & Baglioni, C. (2019). Insomnia as a predictor of mental disorders: a systematic review and meta-analysis. *Sleep medicine reviews*, *43*, 96-105.
[66] Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011). The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. *Sleep*, *34*(5), 601-608.
[67] Baglioni, C., Battagliese, G., Feige, B., Spiegelhalder, K., Nissen, C., Voderholzer, U., ... & Riemann, D. (2011). Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. *Journal of affective disorders*, *135*(1-3), 10-19
[68] Bastien, C. H., Vallières, A., & Morin, C. M. (2001). Validation of the Insomnia Severity Index as an outcome measure for insomnia research. *Sleep medicine*, *2*(4), 297-307.
[69] Breslau, N., Roth, T., Rosenthal, L., & Andreski, P. (1996). Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. *Biological psychiatry*, *39*(6), 411-418.
[70] Almojali, A. I., Almalki, S. A., Alothman, A. S., Masuadi, E. M., & Alaqeel, M. K. (2017). The prevalence and association of stress with sleep quality among medical students. *Journal of epidemiology and global health*, *7*(3), 169-174
[71] Roth, T. (2007). Insomnia: definition, prevalence, etiology, and consequences. *Journal of clinical sleep medicine*, *3*(5 suppl), S7-S10.
[72] Morin, C. M., Bootzin, R. R., Buysse, D. J., Edinger, J. D., Espie, C. A., & Lichstein, K. L. (2006). Psychological and behavioral treatment of insomnia: update of the recent evidence (1998–2004). *Sleep*, *29*(11), 1398-1414
[73] Nyarko, R. O., Kumar, R., Sharma, S., Chourasia, A., Roy, A., & Saha, P. (2022). Antibacterial Activity of Herbal Plant-Tinospora Cordifolia And Catharnthus Roseus.
[74] Tagliazucchi, E., & Laufs, H. (2014). Decoding wakefulness levels from typical fMRI resting-state data reveals reliable drifts between wakefulness and sleep. *Neuron*, *82*(3), 695-708
[75] Ohayon, M. M., & Roth, T. (2003). Place of chronic insomnia in the course of depressive and anxiety disorders. *Journal of psychiatric research*, *37*(1), 9-15.
[76] Daharia, A., Jaiswal, V. K., Royal, K. P., Sharma, H., Joginath, A. K., Kumar, R., & Saha, P. (2022). A Comparative review on ginger and garlic with their pharmacological Action. *Asian Journal of Pharmaceutical Research and Development*, *10*(3), 65-69.
[77] Germain, A. (2013). Sleep disturbances as the hallmark of PTSD: where are we now?. *American Journal of Psychiatry*, *170*(4), 372-382.
[78] Nyarko, R. O., Boateng, E., Kahwa, I., & Boateng, P. O. (2020). A comparison analysis on remdesivir, favipiravir, hydroxychloroquine, chloroquine and azithromycin in the treatment of corona virus disease 2019 (COVID-19)-A Review. *World J. Pharm. Pharm. Sci*, *9*, 121-133.
[79] Li, L., Wu, C., Gan, Y., Qu, X., & Lu, Z. (2016). Insomnia and the risk of depression: a meta-analysis of prospective cohort studies. *BMC psychiatry*, *16*(1), 1-16
[80] Kumar, R., Jain, A., Tripathi, A. K., & Tyagi, S. (2021, January). Covid-19 outbreak: An epidemic analysis using time series prediction model. In *2021 11th international conference on cloud computing, data science & engineering (Confluence)* (pp. 1090-1094). IEEE.
[81] Purabisaha, R. K., Rawat, S. S. N., & Prakash, A. (2021). A Review On Novel Drug Delivery System.
[82] Keshamma, E., Paswan, S. K., Kumar, R., Saha, P., Trivedi, U., Chourasia, A., & Otia, M. (2022). Alkaloid Based Chemical Constituents of Ocimum santum & Cinchona Bark: A Meta Analysis. *Journal for Research in Applied Sciences and Biotechnology*, *1*(2), 35-42
[83] SHAFQAT ZAIDI, R. K., MEHRA, D., SACHIN, T., & ROSHAN, K. A. D. (2021). Effect of Kalahari Cactus Extract on Appetitte, Body Weight And Lipid Profile In Cafeteria Diet Induced Obesity In Experimental Animal. *Annals of the Romanian Society for Cell Biology*, *25*(6), 13976-13987.
[84] Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. *Journal of clinical sleep medicine*, *13*(2), 307-349
[85] Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., ... & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. *Journal of sleep research*, *26*(6), 675-700.
[86] Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011). The Insomnia Severity Index: psychometric

ISSN: 2583-4053
Volume-2 Issue-2 || April 2023 || PP. 14-26

https://doi.org/10.55544/jrasb.2.2.3

indicators to detect insomnia cases and evaluate treatment response. *Sleep*, *34*(5), 601-608.
[87] Van Straten, A., van der Zweerde, T., Kleiboer, A., Cuijpers, P., Morin, C. M., & Lancee, J. (2018). Cognitive and behavioral therapies in the treatment of insomnia: a meta-analysis. *Sleep medicine reviews*, *38*, 3-16.
[88] Riemann, D., Benz, F., Dressle, R. J., Espie, C. A., Johann, A. F., Blanken, T. F., ... & Van Someren, E. J. (2022). Insomnia disorder: State of the science and challenges for the future. *Journal of Sleep Research*, *31*(4), e13604.
[89] Wickwire, E. M., Shaya, F. T., & Scharf, S. M. (2016). Health economics of insomnia treatments: the return on investment for a good night's sleep. *Sleep medicine reviews*, *30*, 72-82.
[90] Arnedt, J. T., Conroy, D. A., Mooney, A., Furgal, A., Sen, A., & Eisenberg, D. (2021). Telemedicine versus face-to-face delivery of cognitive behavioral therapy for insomnia: a randomized controlled noninferiority trial. *Sleep*, *44*(1), zsaa136.
[91] Blom, K., Jernelöv, S., Kraepelien, M., Bergdahl, M. O., Jungmarker, K., Ankartjärn, L., ... & Kaldo, V. (2015). Internet treatment addressing either insomnia or depression, for patients with both diagnoses: a randomized trial. *Sleep*, *38*(2), 267-277.
[92] Lowe, H., Haddock, G., Mulligan, L. D., Gregg, L., Fuzellier-Hart, A., Carter, L. A., & Kyle, S. D. (2019). Does exercise improve sleep for adults with insomnia? A systematic review with quality appraisal. *Clinical psychology review*, *68*, 1-12.
[93] Myllymäki, T., Kyröläinen, H., Savolainen, K., Hokka, L., Jakonen, R., Juuti, T., ... & Rusko, H. (2011). Effects of vigorous late-night exercise on sleep quality and cardiac autonomic activity. *Journal of sleep research*, *20*(1pt2), 146-153
[94] Keshamma, E., Paswan, S. K., Kumar, R., Saha, P., Trivedi, U., Chourasia, A., & Otia, M. (2022). Alkaloid Based Chemical Constituents of Ocimum santum & Cinchona Bark: A Meta Analysis. *Journal for Research in Applied Sciences and Biotechnology*, *1*(2), 35-42.
[95] La, Y. K., Choi, Y. H., Chu, M. K., Nam, J. M., Choi, Y. C., & Kim, W. J. (2020). Gender differences influence over insomnia in Korean population: A cross-sectional study. *PLoS One*, *15*(1), e0227190.
[96] Amle, V. S., Rathod, D. A., Keshamma, E., Kumar, V., Kumar, R., & Saha, P. (2022). Bioactive Herbal Medicine Use for Eye Sight: A Meta Analysis. *Journal for Research in Applied Sciences and Biotechnology*, *1*(3), 42-50.
[97] Kumar, R., Saha, P., Keshamma, E., Sachitanadam, P., & Subramanian, M. (2022). Docking studies of some novel Hetrocyclic compound as Acat inhibitors: A meta analysis. *Journal for Research in Applied Sciences and Biotechnology*, *1*(3), 33-41.
[98] Pandey, M., Singh, A., Agnihotri, N., Kumar, R., Saha, P., Pandey, R. P., & Kumar, A. (2022). Clinical Pharmacology & Therapeutic uses of Diuretic Agents: A Review. *Journal for Research in Applied Sciences and Biotechnology*, *1*(3), 11-20
[99] Roecker, A. J., Cox, C. D., & Coleman, P. J. (2016). Orexin receptor antagonists: new therapeutic agents for the treatment of insomnia. *Journal of Medicinal Chemistry*, *59*(2), 504-530.
[100] Roecker, A. J., Cox, C. D., & Coleman, P. J. (2018). Receptor antagonists: new therapeutic agents for the treatment of insomnia. *Journal of Medicinal Chemistry*, *59*(2), 504-530.
[101] Thiart, H., Ebert, D. D., Lehr, D., Nobis, S., Buntrock, C., Berking, M., ... & Riper, H. (2016). Internet-based cognitive behavioral therapy for insomnia: a health economic evaluation. *Sleep*, *39*(10), 1769-1778.
[102] Blom, K., Jernelöv, S., Rück, C., Lindefors, N., & Kaldo, V. (2017). Three-year follow-up comparing cognitive behavioral therapy for depression to cognitive behavioral therapy for insomnia, for patients with both diagnoses. *Sleep*, *40*(8).
[103] Blom, K., Jernelöv, S., Rück, C., Lindefors, N., & Kaldo, V. (2017). Three-year follow-up comparing cognitive behavioral therapy for depression to cognitive behavioral therapy for insomnia, for patients with both diagnoses. *Sleep*, *40*(8).
[104] Ellis, J. G., Cushing, T., & Germain, A. (2015). Treating acute insomnia: a randomized controlled trial of a “single-shot” of cognitive behavioral therapy for insomnia. *Sleep*, *38*(6), 971-978.
[105] Kumar, R., Keshamma, E., Kumari, B., Kumar, A., Kumar, V., Janjua, D., & Billah, A. M. (2022). Burn Injury Management, Pathophysiology and Its Future Prospectives. *Journal for Research in Applied Sciences and Biotechnology*, *1*(4), 78-89.
[106] Rosenberg, R., Citrome, L., & Drake, C. L. (2021). Advances in the treatment of chronic insomnia: a narrative review of new nonpharmacologic and pharmacologic therapies. *Neuropsychiatric Disease and Treatment*, 2549-2566.
[107] Kumar, R., Saha, P., Kahwa, I., Boateng, E. A., Boateng, P. O., & Nyarko, R. O. (2022). Biological Mode of Action of Phospholipase A and the Signalling and Pro and Anti Inflammatory Cytokines: A Review. *Journal of Advances in Medicine and Medical Research*, *34*(9), 1-10.
[108] Araújo, T., Jarrin, D. C., Leanza, Y., Vallières, A., & Morin, C. M. (2017). Qualitative studies of insomnia: Current state of knowledge in the field. *Sleep medicine reviews*, *31*, 58-69
[109] Blom, K., Jernelöv, S., Kraepelien, M., Bergdahl, M. O., Jungmarker, K., Ankartjärn, L., ... & Kaldo, V. (2015). Internet treatment addressing either insomnia or depression, for patients with both diagnoses: a randomized trial. *Sleep*, *38*(2), 267-277.
[110] Kumar, R., Saha, P., Kahwa, I., Boateng, E. A., Boateng, P. O., & Nyarko, R. O. (2022). Biological Mode of Action of Phospholipase A and the Signalling and Pro and Anti Inflammatory Cytokines: A

ISSN: 2583-4053
Volume-2 Issue-2 || April 2023 || PP. 14-26
https://doi.org/10.55544/jrasb.2.2.3

Review. *Journal of Advances in Medicine and Medical Research*, *34*(9), 1-10.
[111] Prajapati, A. K., Sagar, S., & Kumar, R. (2022). Past and Current Prospectives of Herbal Product for Skin Care. *Journal for Research in Applied Sciences and Biotechnology*, *1*(5), 145-160.
[112] Streatfeild, J., Smith, J., Mansfield, D., Pezzullo, L., & Hillman, D. (2021). The social and economic cost of sleep disorders. *Sleep*, *44*(11), zsab132.
[113] Barnes, C. M., & Watson, N. F. (2019). Why healthy sleep is good for business. *Sleep medicine reviews*, *47*, 112-118.
[114] Troiano, R. P., McClain, J. J., Brychta, R. J., & Chen, K. Y. (2014). Evolution of accelerometer methods for physical activity research. *British journal of sports medicine*, *48*(13), 1019-1023.
[115] Keshri, S., Kumar, R., Kumar, D., Singhal, T., Giri, S., Sharma, I., & Vatsha, P. (2022). Insights Of Artificial Intelligence In Brain Disorder With Evidence Of Opportunity And Future Challenges. *Journal of Pharmaceutical Negative Results*, 10853-10867.
[116] Fang, H., Tu, S., Sheng, J., & Shao, A. (2019). Depression in sleep disturbance: a review on a bidirectional relationship, mechanisms and treatment. *Journal of cellular and molecular medicine*, *23*(4), 2324-2332.
[117] Subramanian, M., Keshamma, E., Janjua, D., Kumar, D., Kumar, R., Saha, P., ... & Rao, S. (2022). Quality Risk Management Approach for Drug Development and Its Future Prospectives. *Journal for Research in Applied Sciences and Biotechnology*, *1*(3), 166-177.
[118] Freeman, D., Sheaves, B., Waite, F., Harvey, A. G., & Harrison, P. J. (2020). Sleep disturbance and psychiatric disorders. *The Lancet Psychiatry*, *7*(7), 628-637.
[119] Kumar, R., Singh, A., & Painuly, N. (2022). Investigation of in-vitro anti-oxidant & anti-ulcer activity of polyherbal medicinal plants. *Journal of Pharmaceutical Negative Results*, 2077-2088.
[120] Van Someren, E. J. (2021). Brain mechanisms of insomnia: new perspectives on causes and consequences. *Physiological reviews*, *101*(3), 995-1046.
[121] Saha, P. (2020). Evolution of tolbutamide in the treatment of diabetes mellitus. *Diabetes*, *2*(10).
[122] Cuijpers, P., Noma, H., Karyotaki, E., Vinkers, C. H., Cipriani, A., & Furukawa, T. A. (2020). A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. *World Psychiatry*, *19*(1), 92-107.
[123] Nyarko, R. O., Kumar, R., Sharma, S., & Chourasia, A. (2022). Ayushmann Roy, and Purabi Saha.". *Antibacterial Activity Of Herbal Plant-Tinospora Cordifolia And Catharnthus Roseus*.
[124] Cunningham, J. E., & Shapiro, C. M. (2018). Cognitive Behavioural Therapy for Insomnia (CBT-I) to treat depression: A systematic review. *Journal of psychosomatic research*, *106*, 1-12.
[125] Keshamma, E., Kumar, A., Jha, R., Amle, V. S., Dudhate, G. S., Patel, D., ... & Kumar, R. (2022). Breast Cancer Treatment Relying on Herbal Bioactive Components. *Journal for Research in Applied Sciences and Biotechnology*, *1*(4), 105-115.
[126] Gebara, M. A., Siripong, N., DiNapoli, E. A., Maree, R. D., Germain, A., Reynolds, C. F., ... & Karp, J. F. (2018). Effect of insomnia treatments on depression: A systematic review and meta-analysis. *Depression and anxiety*, *35*(8), 717-731.
[127] Hasan, F., Tu, Y. K., Yang, C. M., Gordon, C. J., Wu, D., Lee, H. C., ... & Chiu, H. Y. (2022). Comparative efficacy of digital cognitive behavioral therapy for insomnia: a systematic review and network meta-analysis. *Sleep medicine reviews*, *61*, 101567.
[128] Asarnow, L. D., & Manber, R. (2019). Cognitive behavioral therapy for insomnia in depression. *Sleep medicine clinics*, *14*(2), 177-184.
[129] Ye, Y. Y., Zhang, Y. F., Chen, J., Liu, J., Li, X. J., Liu, Y. Z., ... & Jiang, X. J. (2015). Internet-based cognitive behavioral therapy for insomnia (ICBT-i) improves comorbid anxiety and depression—a meta-analysis of randomized controlled trials. *PLoS One*, *10*(11), e0142258.
[130] Ye, Y. Y., Zhang, Y. F., Chen, J., Liu, J., Li, X. J., Liu, Y. Z., ... & Jiang, X. J. (2015). Internet-based cognitive behavioral therapy for insomnia (ICBT-i) improves comorbid anxiety and depression—a meta-analysis of randomized controlled trials. *PLoS One*, *10*(11), e0142258.
[131] Ballesio, A., Aquino, M. R. J. V., Feige, B., Johann, A. F., Kyle, S. D., Spiegelhalder, K., ... & Baglioni, C. (2018). The effectiveness of behavioural and cognitive behavioural therapies for insomnia on depressive and fatigue symptoms: a systematic review and network meta-analysis. *Sleep medicine reviews*, *37*, 114-129.
[132] Forsell, E., Jernelöv, S., Blom, K., Kraepelien, M., Svanborg, C., Andersson, G., ... & Kaldo, V. (2019). Proof of concept for an adaptive treatment strategy to prevent failures in internet-delivered CBT: a single-blind randomized clinical trial with insomnia patients. *American Journal of Psychiatry*, *176*(4), 315-323.
[133] Kaldo, V., Jernelöv, S., Blom, K., Ljótsson, B., Brodin, M., Jörgensen, M., ... & Lindefors, N. (2015). Guided internet cognitive behavioral therapy for insomnia compared to a control treatment–a randomized trial. *Behaviour Research and Therapy*, *71*, 90-100.
[134] Natsky, A. N., Vakulin, A., Chai-Coetzer, C. L., Lack, L., McEvoy, R. D., Lovato, N., ... & Kaambwa, B. (2020). Economic evaluation of cognitive behavioural therapy for insomnia (CBT-I) for improving health outcomes in adult populations: a systematic review. *Sleep Medicine Reviews*, *54*, 101351.

ISSN: 2583-4053
Volume-2 Issue-2 || April 2023 || PP. 14-26

https://doi.org/10.55544/jrasb.2.2.3

[135] Van der Zweerde, T., Van Straten, A., Effting, M., Kyle, S. D., & Lancee, J. (2019). Does online insomnia treatment reduce depressive symptoms? A randomized controlled trial in individuals with both insomnia and depressive symptoms. *Psychological medicine*, *49*(3), 501-509.
[136] Sadler, P., McLaren, S., Klein, B., Harvey, J., & Jenkins, M. (2018). Cognitive behavior therapy for older adults with insomnia and depression: a randomized controlled trial in community mental health services. *Sleep*, *41*(8), zsy104.
[137] Ye, Y. Y., Chen, N. K., Chen, J., Liu, J., Lin, L., Liu, Y. Z., ... & Jiang, X. J. (2016). Internet-based cognitive–behavioural therapy for insomnia (ICBT-i): a meta-analysis of randomised controlled trials. *BMJ open*, *6*(11), e010707.
[138] Mirchandaney, R., Barete, R., & Asarnow, L. D. (2022). Moderators of cognitive behavioral treatment for insomnia on depression and anxiety outcomes. *Current Psychiatry Reports*, *24*(2), 121-128.
[139] Luik, A. I., van der Zweerde, T., van Straten, A., & Lancee, J. (2019). Digital delivery of cognitive behavioral therapy for insomnia. *Current psychiatry reports*, *21*, 1-8.
[140] Wassing, R., Benjamins, J. S., Talamini, L. M., Schalkwijk, F., & Van Someren, E. J. (2019). Overnight worsening of emotional distress indicates maladaptive sleep in insomnia. *Sleep*, *42*(4), zsy268.